Brokerages expect Pulmatrix Inc (NASDAQ:PULM) to announce ($0.39) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Pulmatrix’s earnings. Pulmatrix posted earnings of ($1.30) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 70%. The business is scheduled to issue its next earnings results on Friday, August 2nd.

According to Zacks, analysts expect that Pulmatrix will report full-year earnings of ($2.04) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($1.73) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Pulmatrix.

Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01).

Several analysts have recently weighed in on PULM shares. HC Wainwright restated a “buy” rating on shares of Pulmatrix in a research report on Tuesday, April 16th. Zacks Investment Research upgraded shares of Pulmatrix from a “hold” rating to a “buy” rating in a research report on Saturday, April 20th.

Shares of Pulmatrix stock opened at $0.92 on Wednesday. Pulmatrix has a 52-week low of $0.72 and a 52-week high of $5.90. The business has a 50 day moving average price of $0.98. The stock has a market capitalization of $16.64 million, a P/E ratio of -0.18 and a beta of 1.33.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

Featured Article: What are the FAANG Stocks?

Get a free copy of the Zacks research report on Pulmatrix (PULM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with's FREE daily email newsletter.